Tiziana Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit
NEW YORK & LONDON, August 16, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces today that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit.
About Tiziana Life Sciences plc
Tiziana Life Sciences plc (NASDAQ: TLSA) (LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.
For further information:
Tiziana Life Sciences plc
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q3 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.
To request complimentary investor registration: please click here: Complimentary Investor Registration
Sasha Murray at email@example.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange
. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org
or visit www.rns.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK
regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange